on MAbxience
MAbxience Partners with OncoPrecision for ONC001 ADC Candidate Development
mAbxience, a subsidiary of Fresenius SE, has announced an agreement with OncoPrecision to develop and manufacture OncoPrecision's antibody-drug conjugate (ADC) candidate, ONC001. OncoPrecision, known for precision therapies targeting aggressive cancers, is advancing ONC001 towards Phase I clinical trials.
The collaboration involves mAbxience handling the antibody development for ONC001, including cell line and GMP-grade material production for clinical trials. ONC001 targets CD64, aiming to treat acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), which have limited treatment options.
As part of the agreement, mAbxience has made a strategic investment in OncoPrecision. Jurgen Van Broeck, CEO of mAbxience, will join OncoPrecision's Board as an observer. Financial details remain confidential.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAbxience news